Literature DB >> 18813809

Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.

S Bierer1, E Herrmann, T Köpke, J Neumann, E Eltze, L Hertle, C Wülfing.   

Abstract

The vascular endothelial growth factors VEGF-C, VEGF-D and its receptor, VEGFR-3, are overexpressed in different malignancies and associated with lymph node metastasis and poor prognosis. We analysed these factors in clear cell (ccRCC) and papillary (pRCC) renal cell carcinoma (RCC). The results were correlated with various clinicopathological parameters (CPP). We constructed a tissue microarray with tumor samples of 135 (81%) ccRCC and 31 (19%) pRCC. After immunohistochemical staining using polyclonal antibodies for VEGF-C, VEGF-D and VEGFR-3, a semiquantitative analysis was performed to determine the levels of expression. The results were compared between the two subgroups and were correlated with CPP. In the two subgroups the expression of VEGF-C was significantly correlated with that of VEGF-D (p<0.001). There was an increased expression of VEGF-C in 11% of ccRCC and 36% of pRCC (p=0.002). VEGF-D expression was positive by means of analysis in 22% of ccRCC and 42% of pRCC (p=0.039). There was no significant difference regarding the expression of VEGFR-3 between the subgroups (44% ccRCC and 61% pRCC, p=0.11). No correlation was found between the expression of the analysed parameters and CPP (TNM, grading, progression-free survival and overall survival) in either the entire group or in the two subgroups. In summary, ccRCC and pRCC show a different expression pattern of the analysed lymphangiogenic factors. Further studies are necessary to confirm these results and to determine whether the VEGF-C/VEGF-D/VEGFR-3-axis can play a role as a prognostic tool or a target for therapeutic intervention in renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18813809

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

Review 1.  Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies.

Authors:  Christopher Montemagno; Frédéric Luciano; Gilles Pagès
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3.

Authors:  Ming-Chuan Hsu; Mei-Ren Pan; Wen-Chun Hung
Journal:  Cells       Date:  2019-03-21       Impact factor: 6.600

3.  VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness.

Authors:  Papa Diogop Ndiaye; Maeva Dufies; Sandy Giuliano; Laetitia Douguet; Renaud Grépin; Jérôme Durivault; Philippe Lenormand; Natacha Glisse; Janita Mintcheva; Valérie Vouret-Craviari; Baharia Mograbi; Maud Wurmser; Damien Ambrosetti; Nathalie Rioux-Leclercq; Pascal Maire; Gilles Pagès
Journal:  Theranostics       Date:  2019-01-21       Impact factor: 11.556

4.  The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma.

Authors:  Hao Yu; Shiqian Zhang; Renhua Zhang; Linlin Zhang
Journal:  J Exp Clin Cancer Res       Date:  2009-07-09

5.  Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

Authors:  Charles S Harmon; Samuel E DePrimo; Robert A Figlin; Gary R Hudes; Thomas E Hutson; M Dror Michaelson; Sylvie Négrier; Sindy T Kim; Xin Huang; J Andrew Williams; Tim Eisen; Robert J Motzer
Journal:  Cancer Chemother Pharmacol       Date:  2013-11-13       Impact factor: 3.333

6.  Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with pathological parameters and prognosis.

Authors:  Linna Shi; Ruihua Lv; Chen Li; Dong Han; Zhanli Ren; Ge Ren
Journal:  Transl Androl Urol       Date:  2020-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.